Skip to main content
Geneviève Shemie, Associate | Intellectual Property

Geneviève Shemie

Associate Fasken
Jurisdiction Ontario, 2025 | Québec, 2023
Language(s) French, English
Office(s) Montréal
Contact
Share
  • LinkedIn

Overview

Genevieve is a life sciences lawyer, practicing in the area of health and food regulation in Fasken’s intellectual property group in our Montréal office. She advises manufacturers on all stages of the lifecycle of a pharmaceutical product, from conception to consumers. She also advises clients on IP strategy development and protection.

Genevieve holds both a Juris Doctor (JD) and a Bachelor of Civil Law (BCL) from McGill University. This allows her to counsel clients through both common law and Québec civil law lenses on a wide variety of services—from advising on regulatory compliance to managing intellectual property assets. 

Genevieve has experience in regulatory and compliance responsibilities of life science companies, including advising on the launch of a new health product in Canada, providing guidance through Health Canada investigations and recalls, reviewing advertising material, developing patient support programs, and advising on drug and medical device pricing and reimbursement questions. Genevieve also provides strategic counselling to companies of all sizes for the management of their intellectual property assets, including trademark, patent and copyright protection.

During law school, Genevieve worked with the McGill Center of Genomic and Policy to publish works on the integration of novel medicines and biotechnology into the Canadian healthcare system.

Career & Education

Education

  • JD McGill University
  • BCL McGill University

Community involvement

  • Volunteer Researcher, Legal Information Clinic at McGill (2019-2020)
  • Research Assistant, Center for Research Action on Race Relations (2020-2021)

Memberships & Affiliations

  • Vice-President of Finance, McGill Law Negotiation Club (2019-2021)

Knowledge

  • Dormant DINs Revisited: MFN Pricing and the Evolving Impacts on Canada’s Patent Linkage Regime, 5/20/2026
  • A New Channel: Spirit-Based Ready-to-Drink Beverages in Quebec Grocery Stores, 4/20/2026
  • NEW: Ad Standards’ Updated Code for Food & Beverage Advertising to Children, 4/14/2026
  • CFIA Addresses Stakeholders’ “Eggspectations” Regarding Proposed Guidance on Plant‑Based Egg Alternatives, 4/7/2026
  • Could Artificial Intelligence Soon Prescribe Drugs in Canada? Lessons from Utah's Landmark Program, 3/12/2026
  • Final Changes to Quebec’s Exceptional Patient Measure to Come Into Effect, 12/9/2025
  • Pharma and Device Compliance in Canada 2024 - 2025 Year In Review, 6/5/2025
  • Bill 83 and Its Implications on Québec’s Physicians and Health Care System, 5/15/2025
  • Doing E-Commerce In Canada? Here’s What You Need To Know, 5/8/2025
  • Proposed Regulations to Mitigate Drug and Device Shortages in Canada, 2/28/2025

News

Publications

  • Considering A Telemedicine Or Virtual Care Business In Canada? Here's What You Need To Know Health Law Bulletin, 1/22/2024
  • The Equitable Implementation of Cystic Fibrosis Personalized Medicines in Canada, 4/22/2021
  • Amendments to the Canadian Bail Hearing: Bill C-75 and COVID-19, 9/1/2020